21 USC 813 - Treatment of controlled substance analogues

U.S Code last checked for updates: Nov 22, 2024

§ 813.

Treatment of controlled substance analogues

(a)

In general

(b)

Determination

In determining whether a controlled substance analogue was intended for human consumption under subsection (a), the following factors may be considered, along with any other relevant factors:

(1)

The marketing, advertising, and labeling of the substance.

(2)

The known efficacy or usefulness of the substance for the marketed, advertised, or labeled purpose.

(3)

The difference between the price at which the substance is sold and the price at which the substance it is purported to be or advertised as is normally sold.

(4)

The diversion of the substance from legitimate channels and the clandestine importation, manufacture, or distribution of the substance.

(5)

Whether the defendant knew or should have known the substance was intended to be consumed by injection, inhalation, ingestion, or any other immediate means.

(6)

Any controlled substance analogue that is manufactured, formulated, sold, distributed, or marketed with the intent to avoid the provisions of existing drug laws.

(c)

Limitation

(Pub. L. 91–513, title II, § 203, as added Pub. L. 99–570, title I, § 1202, Oct. 27, 1986, 100 Stat. 3207–13; amended Pub. L. 100–690, title VI, § 6470(c), Nov. 18, 1988, 102 Stat. 4378; Pub. L. 115–271, title III, § 3241, Oct. 24, 2018, 132 Stat. 3950.)

cite as: 21 USC 813